| Persistence and evolution of SARS-CoV-2 in an immunocompromised host B Choi, MC Choudhary, J Regan, JA Sparks, RF Padera, X Qiu, ... New England Journal of Medicine 383 (23), 2291-2293, 2020 | 1160 | 2020 |
| The spliceosome is a therapeutic vulnerability in MYC-driven cancer TYT Hsu, LM Simon, NJ Neill, R Marcotte, A Sayad, CS Bland, ... Nature 525 (7569), 384-388, 2015 | 464 | 2015 |
| A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis JD Kessler, KT Kahle, T Sun, KL Meerbrey, MR Schlabach, EM Schmitt, ... Science 335 (6066), 348-353, 2012 | 459 | 2012 |
| MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis A Terunuma, N Putluri, P Mishra, EA Mathé, TH Dorsey, M Yi, TA Wallace, ... The Journal of clinical investigation 124 (1), 398-412, 2014 | 421 | 2014 |
| Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ KM D’Silva, N Serling-Boyd, R Wallwork, T Hsu, X Fu, EM Gravallese, ... Annals of the rheumatic diseases 79 (9), 1156-1162, 2020 | 306 | 2020 |
| Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance … JA Sparks, ZS Wallace, AM Seet, MA Gianfrancesco, Z Izadi, KL Hyrich, ... Annals of the rheumatic diseases 80 (9), 1137-1146, 2021 | 215 | 2021 |
| Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer EA Bowling, JH Wang, F Gong, W Wu, NJ Neill, IS Kim, S Tyagi, ... Cell 184 (2), 384-403. e21, 2021 | 117 | 2021 |
| Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19 Z Izadi, EJ Brenner, SK Mahil, N Dand, ZZN Yiu, M Yates, RC Ungaro, ... JAMA network open 4 (10), e2129639-e2129639, 2021 | 115 | 2021 |
| Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases C Cook, NJ Patel, KM D’Silva, TYT Hsu, M DiIorio, L Prisco, LW Martin, ... Annals of the rheumatic diseases 81 (2), 289-291, 2022 | 84 | 2022 |
| Association of race and ethnicity with COVID‐19 outcomes in rheumatic disease: data from the COVID‐19 Global Rheumatology Alliance physician registry MA Gianfrancesco, LA Leykina, Z Izadi, T Taylor, JA Sparks, C Harrison, ... Arthritis & Rheumatology 73 (3), 374-380, 2021 | 83 | 2021 |
| Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance MF Ugarte-Gil, GS Alarcón, Z Izadi, A Duarte-García, ... Annals of the rheumatic diseases 81 (7), 970-978, 2022 | 74 | 2022 |
| Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective … SE Sattui, R Conway, MS Putman, AM Seet, MA Gianfrancesco, K Beins, ... The Lancet Rheumatology 3 (12), e855-e864, 2021 | 52 | 2021 |
| SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease KM D’Silva, N Serling-Boyd, TYT Hsu, JA Sparks, ZS Wallace Annals of the rheumatic diseases 80 (6), 817-819, 2021 | 38 | 2021 |
| DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study M Di Iorio, CE Cook, KMM Vanni, NJ Patel, KM D'Silva, X Fu, J Wang, ... Seminars in arthritis and rheumatism 55, 152025, 2022 | 35 | 2022 |
| Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression L Zhang, P Li, T Hsu, HR Aguilar, DE Frantz, JW Schneider, RM Bachoo, ... Differentiation 81 (4), 233-242, 2011 | 35 | 2011 |
| Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative … TYT Hsu, KM D'Silva, NJ Patel, J Wang, AA Mueller, X Fu, L Prisco, ... The Lancet Rheumatology 3 (9), e638-e647, 2021 | 34 | 2021 |
| Coronavirus disease 2019 outcomes among recipients of anti‐CD20 monoclonal antibodies for immune‐mediated diseases: a comparative cohort study NJ Patel, KM D'Silva, TYT Hsu, M DiIorio, X Fu, C Cook, L Prisco, L Martin, ... ACR open rheumatology 4 (3), 238-246, 2022 | 32 | 2022 |
| The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor KL Karlin, G Mondal, JK Hartman, S Tyagi, SJ Kurley, CS Bland, TYT Hsu, ... Cell reports 9 (4), 1318-1332, 2014 | 31 | 2014 |
| Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave Y Kawano, NJ Patel, X Wang, CE Cook, KMM Vanni, EN Kowalski, ... Annals of the rheumatic diseases 81 (12), 1742-1749, 2022 | 26 | 2022 |
| Incident systemic rheumatic disease following COVID-19 TYT Hsu, KM D'Silva, NJ Patel, X Fu, ZS Wallace, JA Sparks The Lancet Rheumatology 3 (6), e402-e404, 2021 | 26 | 2021 |
